Jianpeng Cai, Haocheng Zhang, Kun Zhu, Feng Zhu, Yan Wang, Sen Wang, Faren Xie, Meng Zhang, Lili Rui, Shuhong Li, Ke Lin, Quanlin Xue, Guanmin Yuan, Hongyu Wang, Yi Zhang, Zhangfan Fu, Jieyu Song, Yanliang Zhang, Jingwen Ai, Wenhong Zhang
{"title":"2022 年 12 月至 2023 年 1 月,BA.5 Omicron 亚变异体在中国的主要再感染风险和严重程度。","authors":"Jianpeng Cai, Haocheng Zhang, Kun Zhu, Feng Zhu, Yan Wang, Sen Wang, Faren Xie, Meng Zhang, Lili Rui, Shuhong Li, Ke Lin, Quanlin Xue, Guanmin Yuan, Hongyu Wang, Yi Zhang, Zhangfan Fu, Jieyu Song, Yanliang Zhang, Jingwen Ai, Wenhong Zhang","doi":"10.1080/22221751.2023.2292071","DOIUrl":null,"url":null,"abstract":"<p><p>Data on reinfection in large Asian populations are limited. In this study, we aimed to evaluate the reinfection rate, disease severity, and time interval between the infections in the symptomatic and asymptomatic populations which are firstl infected with BA.2 Omicron Variant. We retrospectively included adult patients with COVID-19 discharged from four designated hospitals between 27 April 2021 and 30 November 2022, who were interviewed via telephone from 29 January to 1 March 2023. Univariable and multivariable analyses were used to explore risk factors associated with reinfection. A total of 16,558 patients were followed up, during the telephone survey of an average of 310.0 days, 1610 (9.72%) participants self-reported reinfection. The mean time range of reinfection was 257.9 days. The risks for reinfection were analysed using multivariable logistic regression. Patients with severe first infection were at higher risk for reinfection (aORs, 2.50; <i>P</i> < 0.001). The male (aORs,0.82; <i>P</i> < 0.001), the elderly (aORs, 0.44; <i>P</i> < 0.001), and patients with full vaccination (aORs, 0.67; <i>P</i> < 0.001) or booster (aORs, 0.63; <i>P</i> < 0.001) had the lower risk of reinfection. Patients over 60 years of age (aORs,9.02; <i>P</i> = 0.006) and those with ≥2 comorbidities (aORs,11.51; <i>P</i> = 0.016). were at higher risk for severe reinfection. The number of clinical manifestations of reinfection increases in people with severe first infection (aORs, 2.82; <i>P</i> = 0.023). The overall reinfection rate was 9.72%, and the reinfection rate of Omicron-to-Omicron subvariants was 9.50% at one year. The severity of Omicron-Omicron reinfection decreased. Data from our clinical study may provide clinical evidence and bolster response preparedness for future COVID-19 reinfection waves.</p>","PeriodicalId":11602,"journal":{"name":"Emerging Microbes & Infections","volume":null,"pages":null},"PeriodicalIF":8.4000,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10849001/pdf/","citationCount":"0","resultStr":"{\"title\":\"Risk of reinfection and severity with the predominant BA.5 Omicron subvariant China, from December 2022 to January 2023.\",\"authors\":\"Jianpeng Cai, Haocheng Zhang, Kun Zhu, Feng Zhu, Yan Wang, Sen Wang, Faren Xie, Meng Zhang, Lili Rui, Shuhong Li, Ke Lin, Quanlin Xue, Guanmin Yuan, Hongyu Wang, Yi Zhang, Zhangfan Fu, Jieyu Song, Yanliang Zhang, Jingwen Ai, Wenhong Zhang\",\"doi\":\"10.1080/22221751.2023.2292071\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Data on reinfection in large Asian populations are limited. In this study, we aimed to evaluate the reinfection rate, disease severity, and time interval between the infections in the symptomatic and asymptomatic populations which are firstl infected with BA.2 Omicron Variant. We retrospectively included adult patients with COVID-19 discharged from four designated hospitals between 27 April 2021 and 30 November 2022, who were interviewed via telephone from 29 January to 1 March 2023. Univariable and multivariable analyses were used to explore risk factors associated with reinfection. A total of 16,558 patients were followed up, during the telephone survey of an average of 310.0 days, 1610 (9.72%) participants self-reported reinfection. The mean time range of reinfection was 257.9 days. The risks for reinfection were analysed using multivariable logistic regression. Patients with severe first infection were at higher risk for reinfection (aORs, 2.50; <i>P</i> < 0.001). The male (aORs,0.82; <i>P</i> < 0.001), the elderly (aORs, 0.44; <i>P</i> < 0.001), and patients with full vaccination (aORs, 0.67; <i>P</i> < 0.001) or booster (aORs, 0.63; <i>P</i> < 0.001) had the lower risk of reinfection. Patients over 60 years of age (aORs,9.02; <i>P</i> = 0.006) and those with ≥2 comorbidities (aORs,11.51; <i>P</i> = 0.016). were at higher risk for severe reinfection. The number of clinical manifestations of reinfection increases in people with severe first infection (aORs, 2.82; <i>P</i> = 0.023). The overall reinfection rate was 9.72%, and the reinfection rate of Omicron-to-Omicron subvariants was 9.50% at one year. The severity of Omicron-Omicron reinfection decreased. Data from our clinical study may provide clinical evidence and bolster response preparedness for future COVID-19 reinfection waves.</p>\",\"PeriodicalId\":11602,\"journal\":{\"name\":\"Emerging Microbes & Infections\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":8.4000,\"publicationDate\":\"2024-12-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10849001/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Emerging Microbes & Infections\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1080/22221751.2023.2292071\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2024/2/6 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q1\",\"JCRName\":\"IMMUNOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Emerging Microbes & Infections","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/22221751.2023.2292071","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/2/6 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"IMMUNOLOGY","Score":null,"Total":0}
Risk of reinfection and severity with the predominant BA.5 Omicron subvariant China, from December 2022 to January 2023.
Data on reinfection in large Asian populations are limited. In this study, we aimed to evaluate the reinfection rate, disease severity, and time interval between the infections in the symptomatic and asymptomatic populations which are firstl infected with BA.2 Omicron Variant. We retrospectively included adult patients with COVID-19 discharged from four designated hospitals between 27 April 2021 and 30 November 2022, who were interviewed via telephone from 29 January to 1 March 2023. Univariable and multivariable analyses were used to explore risk factors associated with reinfection. A total of 16,558 patients were followed up, during the telephone survey of an average of 310.0 days, 1610 (9.72%) participants self-reported reinfection. The mean time range of reinfection was 257.9 days. The risks for reinfection were analysed using multivariable logistic regression. Patients with severe first infection were at higher risk for reinfection (aORs, 2.50; P < 0.001). The male (aORs,0.82; P < 0.001), the elderly (aORs, 0.44; P < 0.001), and patients with full vaccination (aORs, 0.67; P < 0.001) or booster (aORs, 0.63; P < 0.001) had the lower risk of reinfection. Patients over 60 years of age (aORs,9.02; P = 0.006) and those with ≥2 comorbidities (aORs,11.51; P = 0.016). were at higher risk for severe reinfection. The number of clinical manifestations of reinfection increases in people with severe first infection (aORs, 2.82; P = 0.023). The overall reinfection rate was 9.72%, and the reinfection rate of Omicron-to-Omicron subvariants was 9.50% at one year. The severity of Omicron-Omicron reinfection decreased. Data from our clinical study may provide clinical evidence and bolster response preparedness for future COVID-19 reinfection waves.
期刊介绍:
Emerging Microbes & Infections is a peer-reviewed, open-access journal dedicated to publishing research at the intersection of emerging immunology and microbiology viruses.
The journal's mission is to share information on microbes and infections, particularly those gaining significance in both biological and clinical realms due to increased pathogenic frequency. Emerging Microbes & Infections is committed to bridging the scientific gap between developed and developing countries.
This journal addresses topics of critical biological and clinical importance, including but not limited to:
- Epidemic surveillance
- Clinical manifestations
- Diagnosis and management
- Cellular and molecular pathogenesis
- Innate and acquired immune responses between emerging microbes and their hosts
- Drug discovery
- Vaccine development research
Emerging Microbes & Infections invites submissions of original research articles, review articles, letters, and commentaries, fostering a platform for the dissemination of impactful research in the field.